表紙
市場調査レポート

中国の化学合成ポリペプチド薬産業

Research Report on Chinese Chemosynthetic Polypeptide Drug Industry, 2012

発行 China Research and Intelligence 商品コード 246996
出版日 ページ情報 英文 60 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
中国の化学合成ポリペプチド薬産業 Research Report on Chinese Chemosynthetic Polypeptide Drug Industry, 2012
出版日: 2012年07月12日 ページ情報: 英文 60 Pages
概要

2011年、中国のポリペプチド薬市場の規模は289億人民元を記録し、化学合成ポリペプチド薬はその30.87%を占める89億2,000人民元の規模に達しました。

当レポートでは、中国の化学合成ポリペプチド薬産業の現状と見通しを調査分析し、化学合成ポリペプチドの定義とメリット、世界の化学合成ポリペプチド薬産業の動向、中国における産業の発展の経緯、主な化学合成ポリペプチド薬の消費量の推移と予測、主要8社のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 化学合成ポリペプチドの基本概念

  • 定義
  • 区分
  • メリット
    • 小分子薬に勝るメリット
    • タンパク質薬剤に勝るメリット
  • 産業政策

第2章 世界の化学合成ポリペプチド薬産業

  • 概要
    • 開発コース
    • 競合パターン
    • 市場規模
  • 先進国の主なポリペプチド薬
    • コパクソン
    • リュープロン/リュープリン/Enantone
    • ゾラデックス
    • サンドスタチン

第3章 中国の化学合成ポリペプチド薬産業における製造動向

  • 発展の道筋
  • 参入における障壁
    • 技術面
    • 資本面
    • 政策面
    • 市場面
  • 供給
    • 中国市場における承認済み化学合成ポリペプチド
    • 中国の主要化学合成ポリペプチド製造業者

第4章 中国の化学合成ポリペプチド需要

  • 消費
    • 概要
    • チマルファシン
    • チモペンチン
    • ソマトスタチン
    • オクトレオチド
    • サイロカルシトニン
    • その他
  • 中国の化学合成ポリペプチド市場の現況
    • 総市場
    • チマルファシン
    • チモペンチン
    • ソマトスタチン
    • オクトレオチド
    • サイロカルシトニン
    • その他

第5章 中国の化学合成ポリペプチド薬産業のトップ8社

  • Beijing Novartis Pharma Co., Ltd.
  • Shenzhen Hybio Pharmaceutical Co., Ltd.
  • Saisheng Pharmaceutical Co., Ltd.
  • Beijing Shiqiao Biochemical Pharmaceutical Co., Ltd.
  • Hainan Zhonghe Pharmaceutical Co., Ltd.
  • Merck Serono Co., Ltd.
  • Chengdu DIAO Jiuhong Pharmaceutical Factory
  • Hainan Shuangcheng Pharmaceutical Co., Ltd.

第6章 中国の化学合成ポリペプチド薬産業の発展予測

  • 産業発展動向
  • 供給予測
  • 消費予測
    • 総市場
    • チマルファシン
    • チモペンチン
    • ソマトスタチン
    • オクトレオチド
    • サイロカルシトニン
    • その他
  • 市場規模の予測
    • チマルファシン
    • チモペンチン
    • ソマトスタチン
    • オクトレオチド
    • サイロカルシトニン
  • 競合予測
    • ホットな製品の予測
    • 競合パターンの予測

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Chemosynthetic polypeptide drugs are drugs combining the certain amino acids in chemical methods, which are characterized by favorable curable effects, few side-effects, high specificities and other advantages.

In the pharmaceutical industry, chemosynthetic polypeptides are the focus of attentions. On one hand, the indications of polypeptide drugs are in wide range and the curative effects are obvious, mainly for the application of tumor, metabolism, cardiovascular diseases, infectious diseases, etc. On the other hand, the development-success ratio of polypeptide drugs is high compared to that of traditional drugs and the approval ratio is also obviously higher than that of micromolecule chemical drugs. According to historical data, the approval ratio of polypeptide drugs in clinical research is 23 % to 26 %. As the rapid development of biochemical technologies and generic engineering field, polypeptide drugs are likely to replace the existing medicines.

By the end of 2011, there were 68 polypeptide drugs approved to the market (at least to sell in one country)globally, among which there were 51 treatment drugs mainly used in 14 cure fields, i.e., tumors, immunoregulation, cardiovascular diseases, metabolism, etc. In 2011, the total sales was about USD 20.8 billion. At present, there are over 140 polypeptide drugs globally amidst the clinical trial and also 500 to 600 drugs are at the stage of research before clinical work. In the perspective of history, there were 1.2 new polypeptide drug candidates entering clinical research period annually in the 70s of 20th century. The number of new polypeptide drug candidates was separately 4.6 in the 80s and 9.7 in the 90s. During 2000 and 2008, it was 16.8, with a steady increasing trend.

China's polypeptide drugs start late. A batch of multinational corporations did not introduce polypeptide drugs to China's market until the 1990s. It develops into relatively mature technologies and supporting industries nowadays. According to incomplete statistics, pharmaceutical enterprises specializing in the production of biochemical and biological drugs reaches over 400, among which about 80% produce polypeptide drug preparations or active pharmaceutical ingredients in varying types. The number of manufacturers is gradually on the rise. With the constant improvement of the R&D ability of China's polypeptide drugs, China's polypeptide drugs are fast developing.

In 2011, the market scale of China's polypeptide drugs achieved CNY 28.9 billion. In view of advantages with the low impurity content, costs and so on of chemosynthetic method, compared to gene recombination method and animal and plant extraction method, it rapidly develops. In 2011, the market scale of China's chemosynthetic polypeptide drugs was CNY 8.92 billion, accounting for 30.87% of the total polypeptide drug market.

The annual consumption of China's polypeptide drugs also quickly increases. It was 75.95 million in 2007 and reached 260 million in 2011. The average annual growth rate during the four years was as high as 36%, far higher than the growth rate of market scale, mainly owing to the rapid increasing consumption of the low-price oxytocin. Among them, the production of China's domestic enterprises accounts for the majority, while the prices of imported or foreign branded products are generally over 3 to 5 times that of domestic medicine, the main sales are contributed by foreign-funded enterprises therefore.

In terms of the segmentation varieties, China's chemosynthetic polypeptide drug market is mainly composed of thymalfasin, thymopentin, somatostatin, octreotide and thyrocalcitonin, which is much different from product composition in developed polypeptide drug market abroad. In recent years, although the proportion of the five products in total market drastically declines, from nearly 85% in 2007 to 76% in 2011, in the coming period in the future, the five products will still occupy the major market, which is not only determined by the medicine use habit of China's residents and doctors but also the technological level of China's polypeptide drug manufacturers.

Generally, China's domestic enterprises are still in the period of imitating the polypeptide drugs sold in developed countries. At present, the technological difficulties of the imitation of China's chemosynthetic polypeptide drugs lies in how to produce polypeptide APIs in large scale and at low cost in line with the demand of GMP.

However, it can be seen that China's chemosynthetic polypeptide drug market quickly develops out of nothing. In 2006, the market scale was only CNY 2.63 billion and it surmounted CNY 8.92 billion by 2011. Compared with the compound growth rates of China's market and global market during 2007 and 2011, the former was far higher than the later, separately 25% and 11%.

In the light of the sound trend of China's chemosynthetic polypeptide drugs, with the consideration of the development of China's economy and the increase of medical levels, it is predicted that the market scale of China's chemosynthetic polypeptide drugs will rapidly continue to expand in the future years, reaching CNY 15.7 billion by 2016.

More following information can be acquired through this report:

  • Supply and Demand of China's Chemosynthetic polypeptide drugs
  • Policy Environment of China's Chemosynthetic polypeptide drugs
  • China's Major Manufacturers of Chemosynthetic polypeptide drugs
  • Development Trend of Chemosynthetic polypeptide drugs

Following people are recommended to buy this report:

  • Pharmaceutical Enterprises
  • Manufacturers of APIs (Active Pharmaceutical Ingredients)
  • Investors and Research Institutions Focusing on Chemosynthetic Polypeptide Drug Industry

Table of Contents

1. Basic Concept of Chemosynthetic Polypeptide Drugs

  • 1.1. Definition
  • 1.2. Classification
  • 1.3. Advantages
    • 1.3.1. Advantages over Micromolecule Drugs
    • 1.3.2. Advantages over Protein Drugs
  • 1.4. Industrial Policies
    • 1.4.1. Industrial Administrative Departments
    • 1.4.2. Link of Enterprise Establishment
    • 1.4.3. Link of R&D of New Drugs
    • 1.4.4. Drug Production

2. Global Chemosynthetic Polypeptide Drug Industry

  • 2.1. Overview
    • 2.1.1. Development Course
    • 2.1.2. Competition Pattern
    • 2.1.3. Market Scale
  • 2.2. Major Polypeptide Drugs in Developed Countries
    • 2.2.1. Copaxone
    • 2.2.2. Lupron/Leuplin/Enantone
    • 2.2.3. Zoladex
    • 2.2.4. Sandostatin

3. Production of China's Chemosynthetic Polypeptide Drug Industry, 2011-2012

  • 3.1. Development Course
  • 3.2. Barriers to Entry
    • 3.2.1. Technological Barrier
    • 3.2.2. Capital Barrier
    • 3.2.3. Policy Barrier
    • 3.2.4. Market Barrier
  • 3.3. Supply
    • 3.3.1. Approved Chemosynthetic Polypeptide Drugs in China's Market
    • 3.3.2. Major Manufacturers of Chemosynthetic Polypeptide Drugs in China

4. Demand of China's Chemosynthetic Polypeptide Drugs, 2011-2012

  • 4.1. Consumption
    • 4.1.1. Overview
    • 4.1.2. Thymalfasin Consumption
    • 4.1.3. Thymopentin Consumption
    • 4.1.4. Somatostatin Consumption
    • 4.1.5. Octreotide Consumption
    • 4.1.6. Thyrocalcitonin Consumption
    • 4.1.7. Consumption of Other Chemosynthetic Polypeptide Drugs
  • 4.2. Current Market of China's Chemosynthetic Polypeptide Drugs, 2011
    • 4.2.1. Overall Market
    • 4.2.2. Thymalfasin
    • 4.2.3. Thymopentin
    • 4.2.4. Somatostatin
    • 4.2.5. Octreotide
    • 4.2.6. Thyrocalcitonin
    • 4.2.7. Other Chemosynthetic Polypeptide Drugs

5. Top 8 Enterprises of China's Chemosynthetic Polypeptide Drug Industry, 2011-2012

  • 5.1. Beijing Novartis Pharma Co., Ltd.
  • 5.2. Shenzhen Hybio Pharmaceutical Co., Ltd.
  • 5.3. Saisheng Pharmaceutical Co., Ltd.
  • 5.4. Beijing Shiqiao Biochemical Pharmaceutical Co., Ltd.
  • 5.5. Hainan Zhonghe Pharmaceutical Co., Ltd.
  • 5.6. Merck Serono Co., Ltd.
  • 5.7. Chengdu DIAO Jiuhong Pharmaceutical Factory
  • 5.8. Hainan Shuangcheng Pharmaceutical Co., Ltd.

6. Prediction on Development of China's Chemosynthetic Polypeptide Drug Industry, 2012-2016

  • 6.1. Development Trend of the Industry
  • 6.2. Supply Prediction
  • 6.3. Consumption Prediction
    • 6.3.1. Overall Situation
    • 6.3.2. Thymalfasin
    • 6.3.3. Thymopentin
    • 6.3.4. Somatostatin
    • 6.3.5. Octreotide
    • 6.3.6. Thyrocalcitonin
    • 6.3.7. Other Chemosynthetic Polypeptide Drugs
  • 6.4. Prediction on Market Scale
    • 6.4.1. Thymalfasin
    • 6.4.2. Thymopentin
    • 6.4.3. Somatostatin
    • 6.4.4. Octreotide
    • 6.4.5. Thyrocalcitonin
  • 6.5. Prediction on Market Competition
    • 6.5.1. Prediction on Hot Products
    • 6.5.2. Prediction on Competition Pattern

Selected Charts

  • Chart: Comparison of Main Attributes in Chemosynthetic Polypeptide Drugs with Micromolecule Drugs and Protein Drugs
  • Chart: Market Scale of China's Chemosynthetic Polypeptide Drugs, 2007-2011
  • Chart: Consumption of China's Chemosynthetic Polypeptide Drugs, 2007-2011
  • Chart: Proportion of Top 5 China's Chemosynthetic Polypeptide Drugs in Entire Market, 2007-2011
  • Chart: China's Oxytocin Consumption, 2007-2011
  • Chart: Approved Chemosynthetic Polypeptide Drugs in China's Market, 2012
  • Chart: China's Major Manufacturers of Chemosynthetic Polypeptide Drugs
  • Chart: Consumption of China's Chemosynthetic Polypeptide Drugs, 2007-2011
  • Chart: China's Thymalfasin Consumption, 2007-2011
  • Chart: China's Thymopentin Consumption, 2007-2011
  • Chart: Market Scale of China's Major Chemical Synthesis Polypeptide Drug Varieties, 2011
  • Chart: Market Scale of China's Thymalfasin, 2007-2011
  • Chart: Market Share of China's Major Thymalfasin Manufacturers, 2009-2011
  • Chart: Market Scale of China's Thymopentin, 2007-2011
  • Chart: Sales Volume Share of Chemosynthetic Polypeptide Drugs of Beijing Novartis Pharma Co., Ltd., 2009-2011
  • Chart: Major Products of Shenzhen Hybio Pharmaceutical Co., Ltd.
  • Chart: Market Share of Thymalfasin of Saisheng Pharmaceutical Co., Ltd., 2009-2011
  • Chart: Major Products of Hainan Zhonghe Pharmaceutical Co., Ltd.
  • Chart: Major Products of Merck Serono Co., Ltd. in China
  • Chart: Patent Situation of Global Important Polypeptide Drugs in China
  • Chart: Prediction on Consumption of China's Chemosynthetic Polypeptide Drugs, 2012-2016
  • Chart: Prediction on China's Thymalfasin Consumption, 2012-2016
  • Chart: Prediction on Market Scale of China's Chemosynthetic Polypeptide Drugs, 2012-2016
Back to Top